Abstract
Direct oral anticoagulants (DOACs) have been shown to be superior to vitamin K antagonists (VKAs) in regards to safety and efficacy in numerous clinical trials and are now the preferred oral anticoagulant by multiple professional societies. However, patients with significant levels of organ dysfunction were excluded from all major clinical trials, leaving the clinical benefit in these subsets uncertain. Patients with chronic kidney disease (CKD) specifically often require anticoagulation for acute or long-term indications such as venous thromboembolism, atrial fibrillation, or mechanical heart valves. The efficacy and safety of anticoagulation in patients with renal failure is less certain, however, particularly with DOACs which have altered pharmacokinetics in patients with renal failure and limited observational data on their use in this population. In this review, we compile the most up to date data on the DOAC use in patients with CKD. DOAC use in patients with ESRD and advanced CKD is increasing despite the presence of a clear benefit, and with the potential for increased risk of bleeding compared to warfarin. Apixaban has the greatest amount of outcomes research supporting its use over warfarin in this patient population; however, further research on DOAC safety and efficacy in those with advanced CKD is still needed.
K E Y W O R D S
clinical trials, coagulation disorders has been shown to be a risk factor for vascular calcification in ESRD patients. 1, 4 Additionally, warfarin use has been shown to increase bleeding risk as creatinine clearance decreases. 1 Despite these concerns, it remains the first-line therapy in large part because there is a paucity of clinical data concerning the safety and efficacy of DOACs in advanced kidney disease.
Direct oral anticoagulants, while not currently recommended as a first-line therapy by professional guidelines have been approved by the FDA for use in patients with chronic kidney disease (CKD).
The FDA has approved use of apixaban, rivaroxaban, dabigatran, and edoxaban in patients with CrCl as low as 15 
| PHARMACOK INE TI C DATA AND DOAC APPROVAL IN EUROPE AND THE UNITED S TATE S
Although the pivotal trials that led to DOAC use for AF in the general population did not include patients with CrCl <30, post hoc analysis of these studies and pharmacokinetic data led to approval of the DOACs in CKD as seen in Tables 1 and 2. 1,2,5-7 The FDA and the EMA approved Apixaban, Rivaroxaban, Dabigatran, and Edoxaban in patients with CKD I-III, however, their recommendations on these drugs use in advanced CKD has varied. 1, 2, [8] [9] [10] [11] While all four of these medications are currently approved in some capacity for patients with renal dysfunction, apixaban, and rivaroxaban have been the two DOACs which have increased the most in use over the past several years in patients with advanced CKD. 1, 3 They are also the only two DOACs with FDA approved dosing recommendations for patients undergoing hemodialysis. This is in contrast to the EMA, which has recommended against use of either drug in patients undergoing dialysis. 8, 9 The increase in use in these populations has been primarily supported by small pharmacokinetic and clinical studies for both drugs.
Apixaban has been shown in a study by Wang et This study also showed that among 6 dialysis patients given 10 mg doses daily over 7 days there was minimal drug accumulation. 14 Both trials support the use of reduced dose rivaroxaban in patients with advanced CKD and ESRD, citing similar PK and PD parameters of the drug when compared to healthy volunteers. 14, 15 The fact that 2/3 of rivaroxaban is eliminated by the liver via metabolism to an inactive metabolite and that the 1/3 which is renally eliminated is primarily through secretion rather than filtration also support the hypothesis that rivaroxaban use may be feasible in dialysis patients without significant comorbidities. 14, 15 Dabigatran similarly had small pharmacokinetic studies which paved the way for its approval in patients CKD. This study did not address serial dosing, and considering the accumulation noted in serial dosing of apixaban in ESRD patients further studies are needed to address this concern. 13, 16 Betrixaban was approved in 2017 for use in VTE prophylaxis in hospitalized patients at risk of thromboembolic event but was rejected by the EMA. It is PK parameters are encouraging as it has the lowest renal clearance of any DOAC at 5%-7%, as well as the lowest hepatic metabolism (<1%) and so it may eventually be useful in patients with AF and CKD. 17 It was compared to warfarin in patients with non-valvular AF for thromboprophylaxis and showed significantly decreased bleeding compared to warfarin only at a 40 mg daily dose. 17 Clinical efficacy was not able to be assessed given the small size of the trial. Additionally, only 8.1% of patients in this trial had GFR <40. 17 Although the pharmacokinetics of betrixaban show potential promise for use in patients with renal disease and AF, further clinical data are required prior to use of this drug for this indication.
| CLINI C AL DATA REG ARD ING US E OF DOAC S IN ADVAN CED CK D
Although these pharmacokinetic studies suggest that rivaroxaban, apixaban, and dabigatran are efficacious and safe in patients with ESRD and/or advanced CKD, there are several significant limitations before application in the general population should be considered. First, these studies have small sample sizes and ideal patients with few comorbidities which do not reflect the general population with advanced CKD. These studies also assume that bioavailability of rivaroxaban and apixaban is the same in patients with and without ESRD, however, given that uremia can affect drug-plasma protein binding as well as hepatic metabolism this were stratified by GFR and propensity matched to a control patients taking warfarin. The mean follow-up for patients was 1.2 years and primary outcomes evaluated were bleeding events and ischemic strokes measured using ICD-9 and ICD-10 codes.
This study found that although efficacy of DOACs and warfarin in terms of stroke prevention was equivalent, the DOAC had significantly increased rates of bleeding events. There was a 23%
higher risk of bleeding in patients taking DOACs with an eGFR <60 mL/min compared to patients taking warfarin. This trend was significant for DOACs overall as well as for all individual DOACs which were tested in the study (Dabigatran, Apixaban and Rivaroxaban). This study was primarily comprised of individuals with mild-to-moderate CKD, however, and only 4% of the patient cohort and CrCl <30.
In contrast to this report is a recent study from Siontis et al which looked at apixaban vs warfarin use in patients undergoing dialysis. This study was also retrospective and used ICD-9 and ICD-10 codes for diagnosis; however, the database used was the United
States Renal Data System which reflects Medicare patients. A total of 26 111 patients were included, and 2351 patients on apixaban were analyzed. The authors reported a decreased risk of bleeding in patients taking apixaban compared to warfarin with an equal risk of stroke, systemic embolization, and death. There was increased efficacy of 5 mg BID apixaban over warfarin in terms of stroke prevention and mortality but not of 2.5 mg BID apixaban, which is interesting considering the study by Mavrakanas et al showed that the 5 mg dose in dialysis patients resulted in supratherapeutic levels while the 2.5 mg dose did not. 13 Another retrospective study from Summarizing the limited clinical data casts doubt on the applicability of previous pharmacokinetic studies to a general population with chronic kidney disease. In patients with eGFR <60, there was increased rates of major and minor bleeding in patients taking apixaban, rivaroxaban, and dabigatran compared to those on warfarin. 2 Additionally, dialysis patients experienced increased bleeds and poorer outcomes with rivaroxaban and dabigatran compared to warfarin. 20 Despite this, it appears that there is a potential for apixaban to be used for stroke prevention in patients currently on dialysis as data, summarized in Table 3 , shows similar efficacy to warfarin but with less major bleeding complications. 
| RIS K OF B LEED ING WITH DOAC S IN ADVAN CED CK D
All DOACs rely on renal elimination in some capacity and therefore any decrease in the GFR can affect drug elimination. The level of renal excretion for DOACs in descending order is dabigatran (80%), edoxaban (35%), rivaroxaban (33%), apixaban (25%), and betrixaban (5%-7%). 5, 6, 17, 20 A decrease in GFR can subsequently lead to drug accumulation and further increase patient's risk of side effects, specifically bleeding. Additionally, patients with advanced kidney disease have a higher baseline risk of bleeding due to uremia causing platelet dysfunction. 1 Warfarin is currently the preferred anticoagulant in patients with CKD based on societal guidelines;
however, Warfarin has also been shown to have increased bleeding risk that is inversely proportional to creatinine clearance (CrCl). 
| IMP ORTAN CE OF APPROPRIATE MONITORING OF RENAL FUN C TION
Another important factor to consider with the increasing use of DOACs in patients with advanced CKD is the potential for errors in appropriate dosing due to differences in evaluating renal function. The study by Siontis et al showed that apixaban had less bleeding risk that warfarin; however, the apixaban group still had an overall rate of major bleeding of 3.1 per hundred-person years which is nearly 10 times higher than the bleeding rate in the apixaban cohort of the ARISTOTLE trial. 3 Additionally, the same study showed high rates of discontinuation of anticoagulation in both treatment groups with nearly 2/3 of all patients stopping therapy. This suggests patient intolerance of anticoagulation may have been due to minor bleeding which was not accounted for in the study outcomes.
For the time being, there will have to continue to be individualized clinical decision-making. Figure 1 lists some of the important factors to consider when deciding about anticoagulation for patients with AF and ESRD. Until future studies clarify the picture, this problem will continue to be a question for treatment teams. Future studies will need to continue to address the appropriate dose reduction of various DOACs for patients with advanced CKD or ESRD and will need large-scale clinical outcome data in order to determine which, if any, DOACs should be administered to this population. 
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